PDGFR-beta Inhibitors
Santa Cruz Biotechnology now offers a broad range of PDGFR-beta Inhibitors. The biological effects of Platelet-derived growth factor (PDGF) proteins are mediated via two tyrosine kinase receptors, PDGFR-α and PDGFR-β. PDGF-mediated signaling is critical for development of many organ systems and is important for growth and survival. PDGFR-beta Inhibitors offered by Santa Cruz inhibit PDGFR-beta and, in some cases, other development and tyrosine kinase receptor related proteins. View detailed PDGFR-beta Inhibitor specifications, including PDGFR-beta Inhibitor CAS number, molecular weight, molecular formula and chemical structure, by clicking on the product name.
Items 1 to 10 of 44 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that inhibits PDGFR-β along with other kinases. It is investigated for advanced renal cell carcinoma and hepatocellular carcinoma. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Sunitinib Malate (CAS 341031-54-7) is a chemical compound known for its role as a potent inhibitor of PDGFR-beta. By targeting this protein, it influences specific cellular signaling pathways, offering potential for various applications. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib was one of the first PDGFR-Beta inhibitors developed. It targets several tyrosine kinases, including PDGFR-Beta. | ||||||
VEGFR2 Kinase Inhibitor III | 204005-46-9 | sc-202851 | 5 mg | $165.00 | 7 | |
VEGFR2 Kinase Inhibitor III, effectively hinders PDGFR-beta function. By targeting this protein, it adjusts specific cellular pathways, showing promise for various biological investigations. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib is another tyrosine kinase inhibitor that targets PDGFR-Beta, along with other receptors. | ||||||
PDGFR Tyrosine Kinase Inhibitor III | 205254-94-0 | sc-204173 | 1 mg | $172.00 | 6 | |
PDGFR Tyrosine Kinase Inhibitor III, effectively impedes PDGFR-beta activity. By specifically targeting this protein, it modulates cellular pathways, holding significance for diverse biological studies. | ||||||
AAL-993 | 269390-77-4 | sc-221195 sc-221195A | 5 mg 25 mg | $255.00 $816.00 | ||
AAL-993 (CAS 269390-77-4) is recognized for its role as an inhibitor of PDGFR-beta, a protein integral to cell signaling. By interacting with PDGFR-beta, it modulates specific cellular processes, showcasing its significance in various research contexts. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a multitargeted tyrosine kinase inhibitor with activity against PDGFR-Beta and other kinases. | ||||||
PKC-412 | 120685-11-2 | sc-200691 sc-200691A | 1 mg 5 mg | $52.00 $114.00 | 10 | |
PKC-412 effectively inhibits PDGFR-beta, a protein vital for cellular signaling. By targeting this interaction, it influences specific pathways, showcasing its relevance in diverse biological contexts. | ||||||
AG-1296 | 146535-11-7 | sc-200631 sc-200631A | 5 mg 25 mg | $121.00 $476.00 | 6 | |
AG-1296, effectively hinders PDGFR-beta, a pivotal protein in cellular signaling. By targeting this interaction, it influences specific pathways, holding significance in various biological investigations. | ||||||